NCT05709288View on ClinicalTrials.gov

Gene Therapy for Hemophilia B Patients Aged 12-18 Years Old

PHASE1RecruitingINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

March 23, 2023

Primary Completion Date

June 30, 2035

Study Completion Date

November 30, 2035

Conditions
Hemophilia B
Interventions
DRUG

BBM-H901

Single dose intravenous infusion of BBM-H901, an adeno-associated viral (AAV) vector designed to drive expression of an hyper active human factor IX mutant(FIX Padua) transgene in liver. The dose of BBM-H901 is 5x10'12 vg/Kg.

Trial Locations (1)

300020

RECRUITING

Institute of haematology and Blood diseases hospital, Tianjin

All Listed Sponsors
lead

Institute of Hematology & Blood Diseases Hospital, China

OTHER